Clearstead Advisors’s Kailera Therapeutics KLRA Stock Holding History
Bought
Maintained
Sold
Other funds holding KLRA
Clearstead Advisors's KLRA Position: Q3 2026 in Review
Clearstead Advisors opened a new position in Kailera Therapeutics (KLRA) in Q3 2026: 13 shares worth $149. The stake represents ﹤0.01% of the portfolio and ranks #3165 among its holdings.
129 funds tracked by Wall St. Rank hold KLRA as of Q3 2026.
- Clearstead Advisors held 13 shares of Kailera Therapeutics worth $149 as of Q3 2026.
- Kailera Therapeutics was a new Clearstead Advisors position in Q3 2026.
- Kailera Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #3165 holding.
- 129 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q3 2026.
Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.